Novel Rigidizing Overtube for Gastrointestinal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new tool, the Pathfinder Endoscope Overtube, to determine if it makes endoscopic submucosal dissection—a specific type of cancer surgery—quicker and safer. Researchers aim to find out if this tool enhances doctors' stability and control during operations, potentially reducing complications. Participants suitable for this trial have been referred for surgery to remove certain challenging growths in the colon, such as those with scars or specific tumor types.
As an unphased trial, it allows patients to contribute to innovative surgical advancements that could enhance future procedures.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that the Pathfinder Endoscope Overtube is safe for gastrointestinal procedures?
Research has shown that the new rigidizing overtube, such as the Pathfinder Endoscope Overtube, is generally easy for patients to handle. In one study with 66 patients, the overtube helped keep the scope steady, allowing doctors to perform procedures more smoothly. This finding suggests that the overtube could make the procedure safer and more effective.
Earlier findings also indicate that for hard-to-reach areas in the colon, the overtube kept the scope in place over half the time without slipping. This could lead to fewer complications during the procedure. Overall, the evidence so far indicates that the overtube is safe to use, with no major negative effects reported.12345Why are researchers excited about this trial?
Researchers are excited about the Pathfinder Endoscope Overtube because it introduces a new approach to performing endoscopic submucosal dissection (ESD) for gastrointestinal cancer. Unlike traditional ESD techniques, which rely on manually maneuvering the endoscope, this novel overtube potentially offers enhanced stability and precision during procedures. By stiffening the endoscope, the overtube aims to improve the accuracy of tumor removal, reduce procedure times, and minimize complications, offering a promising advancement in the treatment of gastrointestinal cancers.
What evidence suggests that the Pathfinder Endoscope Overtube is effective for gastrointestinal cancer?
In this trial, participants in the treatment arm will undergo endoscopic submucosal dissection using the Pathfinder Endoscope Overtube. Research has shown that new tools like the Pathfinder Endoscope Overtube can make endoscopic procedures quicker and more stable. Studies have found that this overtube greatly improves the steadiness of the scope, with one study showing 63.6% stability compared to just 24.2% without it. This increased control can reduce the time needed to complete procedures. Additionally, the overtube successfully kept the scope in place during challenging procedures about 55% of the time. Overall, the success rate of using these overtubes in clinical settings is impressively high, at 94.7%.12467
Who Is on the Research Team?
Mohamed O. Othman, MD
Principal Investigator
Baylor College of Medicine
Are You a Good Fit for This Trial?
This trial is for individuals at least 22 years old needing a procedure called ESD for colon tumors. They must have specific types of lesions, like those with scars or certain large spreading tumors, and not be located in the sigmoid colon or rectum. Pregnant or nursing women cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo colonic endoscopic submucosal dissection (ESD) with or without the Pathfinder Endoscope Overtube
Follow-up
Participants are monitored for safety and effectiveness after the procedure
What Are the Treatments Tested in This Trial?
Interventions
- Endoscopic Submucosal Dissection
- Novel Rigidizing Overtube
Endoscopic Submucosal Dissection is already approved in United States for the following indications:
- Facilitate intubation, change of endoscopes, and treatment in the gastrointestinal (GI) tract in adult patients (22 years of age and older)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baylor College of Medicine
Lead Sponsor
Neptune Medical, Inc.
Collaborator